NTLA
Intellia Therapeutics, Inc
Company · XNAS · US · USD
Market price
$12.06
−$2.37 (-16.40%) · 3 months
| Date and time | Price |
|---|---|
| May 11, 2026 | $14.42 |
| May 12, 2026 | $13.99 |
| May 13, 2026 | $14.28 |
| May 14, 2026 | $13.09 |
| May 15, 2026 | $13.67 |
| May 18, 2026 | $12.69 |
| May 19, 2026 | $11.94 |
| May 20, 2026 | $12.26 |
| May 21, 2026 | $12.37 |
| May 22, 2026 | $12.60 |
| May 26, 2026 | $12.61 |
| May 27, 2026 | $13.44 |
| May 28, 2026 | $13.68 |
| May 29, 2026 | $14.07 |
| Jun 1, 2026 | $13.73 |
| Jun 2, 2026 | $13.13 |
| Jun 3, 2026 | $13.02 |
| Jun 4, 2026 | $14.75 |
| Jun 5, 2026 | $13.54 |
| Jun 8, 2026 | $13.49 |
| Jun 9, 2026 | $12.89 |
| Jun 10, 2026 | $12.20 |
| Jun 11, 2026 | $12.35 |
| Jun 12, 2026 | $12.11 |
| Jun 15, 2026 | $14.92 |
| Jun 16, 2026 | $14.55 |
| Jun 17, 2026 | $15.20 |
| Jun 18, 2026 | $15.67 |
| Jun 22, 2026 | $15.75 |
| Jun 23, 2026 | $15.25 |
| Jun 24, 2026 | $15.50 |
| Jun 25, 2026 | $16.03 |
| Jun 26, 2026 | $16.68 |
| Jun 29, 2026 | $16.61 |
| Jun 30, 2026 | $16.92 |
| Jul 1, 2026 | $17.24 |
| Jul 2, 2026 | $17.56 |
| Jul 6, 2026 | $17.84 |
| Jul 7, 2026 | $17.43 |
| Jul 8, 2026 | $16.84 |
| Jul 9, 2026 | $15.44 |
| Jul 10, 2026 | $14.22 |
| Jul 13, 2026 | $13.02 |
| Jul 14, 2026 | $13.30 |
| Jul 15, 2026 | $13.04 |
| Jul 16, 2026 | $11.86 |
| Jul 17, 2026 | $11.38 |
| Jul 20, 2026 | $10.92 |
| Jul 21, 2026 | $11.47 |
| Jul 22, 2026 | $11.13 |
| Jul 23, 2026 | $11.10 |
| Jul 24, 2026 | $10.73 |
| Jul 27, 2026 | $10.67 |
| Jul 28, 2026 | $10.89 |
| Jul 29, 2026 | $10.80 |
| Jul 30, 2026 | $11.09 |
| Jul 31, 2026 | $10.68 |
| Aug 3, 2026 | $10.77 |
| Aug 4, 2026 | $11.32 |
| Aug 5, 2026 | $10.97 |
| Aug 6, 2026 | $11.24 |
| Aug 7, 2026 | $11.94 |
| Aug 10, 2026 | $12.06 |
- Period change
- -16.40%
- Period low
- $10.67
- Period high
- $17.84
- Observations
- 63
- Updated
- Aug 10, 2026, 6:22 PM
About Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- $1,492,233,918.36
- Employees
- 377